Value Investing Research & Market Analysis

Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Allogene Therapeutics, Inc. - Common Stock (NQ:ALLO)

1.020 -0.070 (-6.43%)
Delayed Quote Updated: 10:52 AM EST, Nov 6, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Allogene Therapeutics, Inc. - Common Stock

< Previous 1 2
...
5 6 7 8 9 10 11 12 Next >
News headline image
3 Stocks With Sky-High Short Interest Levels
BYND, BTAI, and ALLO stand out as high short-interest stocks to watch due to their potential for price fluctuations and short-squeeze opportunities. 
Via MarketBeat
News headline image
Allogene Therapeutics to Report Second Quarter 2023 Financial Results on August 2, 2023
From Allogene Therapeutics, Inc.
Via GlobeNewswire
News headline image
Short Squeeze Alert: The 5 Most Shorted Stocks Right Now ↗
Wondering what are the most shorted stocks this year? Here are the top five companies investors are betting against. 
Via InvestorPlace
News headline image
Analyst Ratings for Allogene Therapeutics ↗
 
Via Benzinga
News headline image
Why Allogene Stock Is Trading Down Today ↗
Allogene Therapeutics, Inc. (NASDAQ: ALLO) shares are trading lower after the company announced its CFO Eric Schmidt will step down from his position. 
Via Benzinga
News headline image
Where Allogene Therapeutics Stands With Analysts ↗
 
Via Benzinga
News headline image
The Latest Analyst Ratings for Allogene Therapeutics ↗
 
Via Benzinga
News headline image
Recap: Allogene Therapeutics Q1 Earnings ↗
 
Via Benzinga
News headline image
Allogene Therapeutics' Allogeneic CAR-T Therapy Proves Potential for LBCL Treatment, Analysts See Potential for First-in-Class Status ↗
Thursday, Allogene Therapeutics Inc (NASDAQ: ALLO) presented the updated data from the Phase 1 ALPHA/ALPHA2 trials of ALLO-501/501A in 33 CAR T naïve patients with relapsed/refractory (r/r) large... 
Via Benzinga
News headline image
Allogene Therapeutics Provides Additional ALLO-501/501A Phase 1 Data in an Oral Presentation at the International Conference on Malignant Lymphoma (ICML) Lugano
From Allogene Therapeutics, Inc.
Via GlobeNewswire
News headline image
12 Health Care Stocks Moving In Wednesday's Intraday Session ↗
 
Via Benzinga
News headline image
Allogene Therapeutics Announces Departure of Chief Financial Officer
From Allogene Therapeutics, Inc.
Via GlobeNewswire
News headline image
Where Allogene Therapeutics Stands With Analysts ↗
 
Via Benzinga
News headline image
Why MIND Technology Shares Are Trading Lower By Over 20%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session ↗
Gainers WeTrade Group, Inc. (NASDAQ: WETG) shares climbed 140.3% to $20.28. WeTrade launched large-scale language processing models to increase product applications in the field of artificial... 
Via Benzinga
News headline image
Allogene Therapeutics Announces Oral Presentation of Phase 1 Data on ALLO-501/501A in Large B Cell Lymphoma at the International Conference on Malignant Lymphoma (ICML) Lugano
From Allogene Therapeutics, Inc.
Via GlobeNewswire
News headline image
Allogene Therapeutics Presents Updated ALLO-501/501A Phase 1 Data in Large B Cell Lymphoma at the American Society of Clinical Oncology (ASCO) Annual Meeting
From Allogene Therapeutics, Inc.
Via GlobeNewswire
News headline image
Allogene Therapeutics Announces Participation in Three Upcoming Investor Conferences
From Allogene Therapeutics, Inc.
Via GlobeNewswire
News headline image
The 3 Best Stocks to Short in May 2023 ↗
The best stocks to short are companies whose businesses aren’t faring well and have a higher-than-average short interest. 
Via InvestorPlace
News headline image
7 Short-Interest Stocks to Target for Explosive Gains ↗
For contrarian investors that can stand the heat, short-interest stocks to buy can offer significant rewards in a short time period. 
Via InvestorPlace
News headline image
As Feinstein Returns To Congress, Reports Of Her Stock Profits Upset Aaron Rodgers ↗
Sen. Dianne Feinstein of California, one of the wealthiest members of Congress, continues to draw ire for her questionable stock trading while in office. What Happened: Feinstein, 89, "has some of the... 
Via Benzinga
News headline image
Allogene Therapeutics Announces Encore Presentation of Phase 1 Data from the ALLO-501/501A Trials in Large B Cell Lymphoma at the European Hematology Association (EHA) Hybrid Congress
From Allogene Therapeutics, Inc.
Via GlobeNewswire
News headline image
Zillow, Shopify, Datadog And Other Big Stocks Moving Higher On Thursday ↗
U.S. stocks traded lower, with the Dow Jones falling around 400 points on Thursday. Here are some big stocks recording gains in today’s session. 
Via Benzinga
News headline image
Why Synaptics Shares Are Trading Lower By 17%? Here Are Other Stocks Moving In Thursday's Mid-Day Session ↗
Gainers Qurate Retail, Inc. (NASDAQ: QRTEB) shares jumped 89.3% to $7.44. 
Via Benzinga
News headline image
Allogene Therapeutics Reports First Quarter 2023 Financial Results and Business Update
From Allogene Therapeutics, Inc.
Via GlobeNewswire
News headline image
Allogene Therapeutics Announces Presentation of Phase 1 Data from the ALLO-501/501A Trials in Large B Cell Lymphoma at the American Society of Clinical Oncology (ASCO) Annual Meeting
From Allogene Therapeutics, Inc.
Via GlobeNewswire
News headline image
Xerox, Hubbell, Spotify And Other Big Stocks Moving Higher On Tuesday ↗
U.S. stocks traded lower, with the Nasdaq Composite dropping around 100 points on Tuesday. Here are some big stocks recording gains in today’s session. 
Via Benzinga
News headline image
Allogene Therapeutics to Report First Quarter 2023 Financial Results on May 3, 2023
From Allogene Therapeutics, Inc.
Via GlobeNewswire
News headline image
Allogene Therapeutics Appoints Timothy Moore as Chief Technical Officer
From Allogene Therapeutics, Inc.
Via GlobeNewswire
News headline image
Allogene Therapeutics Presents Interim Phase 1 Data on ALLO-316 in Renal Cell Carcinoma at the American Association of Cancer Research (AACR) Annual Meeting
From Allogene Therapeutics, Inc.
Via GlobeNewswire
News headline image
7 Short-Squeeze Stocks That Could Make You Rich ↗
Although moving against the grain presents its own distinct set of risks, these short-squeeze stocks may profit the contrarian. 
Via InvestorPlace
< Previous 1 2
...
5 6 7 8 9 10 11 12 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.